Search Results

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.

NewAmsterdam Pharma Company N.V. announced that it has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.

Sangamo Therapeutics, Inc. today announced it has signed an evaluation and option agreement with Prevail Therapeutics through which Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets.

BriaCell Therapeutics Corp. announces that the Company has signed a Master Service and Technology Agreement agreement with Prevail InfoWorks, Inc., a Philadelphia, PA based Contract Research Organization, to provide clinical services and technologies for BriaCell’s upcoming pivotal study in advanced metastatic breast cancer.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that Prevail Partners, LLC, an investment fund, has agreed to invest in the Company through a subscription for 11,066,667 ordinary shares at a price of US$0.075 per share for the total sum of $830,000.

BriaCell Therapeutics Corp. is pleased to announce that the Company has completed the previously-announced strategic investment by Prevail Partners, LLC in the Company, in accordance with a stock purchase agreement entered into between the Company and Prevail Partners on May 12, 2023.

Scribe Therapeutics Inc. today announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, granting Prevail exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, announced the completion of the clinical phase of the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL as a potential treatment for fibromyalgia-type Long COVID.

Tonix Pharmaceuticals Holding Corp. announced topline results from the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL 5.6 mg for the management of fibromyalgia-type Long COVID.